News
AbbVie ( ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback